Form 4: BioLife Solutions Officer Sells Shares for Tax Obligations

BioLife Solutions EVP & Chief Scientific Officer, Aby J. Mathew, sold 531 shares of common stock at $25.44 per share to cover tax withholding obligations.

Summary

• Aby J. Mathew, Executive Vice President & Chief Scientific Officer of BioLife Solutions Inc. (BLFS), reported a sale of common stock.
• The transaction involved the disposition of 531 shares of common stock.
• The shares were sold at a price of $25.44 per share.
• The total value of the shares sold was $13,518.84.
• The sale was executed on August 26, 2025.
• This transaction was conducted pursuant to a Rule 10b5-1(c) trading plan, which was adopted on February 24, 2022.
• The purpose of the sale was to satisfy tax withholding obligations related to the vesting of restricted stock.
• Following this transaction, Aby J. Mathew beneficially owns 352,051 shares of common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale for tax withholding purposes under a pre-arranged 10b5-1 plan. It does not reflect a change in management's outlook or confidence in the company, thus indicating a neutral sentiment.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Industry Context

This filing reports a routine, non-discretionary insider transaction for tax purposes, which typically has no bearing on broader industry trends or competitive landscape for BioLife Solutions.

Stakeholder Impact

• Shareholders: Minimal to no direct impact as this is a routine, non-discretionary sale for tax purposes and a small percentage of the company's outstanding shares. It does not signal a change in company fundamentals or management's confidence.

Key Dates

Recommendation

The reported sale by an executive is a routine, non-discretionary transaction executed under a Rule 10b5-1 plan to cover tax obligations from restricted stock vesting. This type of transaction does not typically reflect a change in the executive's view of the company's prospects or fundamental value, and the amount is not significant enough to impact market sentiment. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

BioLife Solutions, BLFS, Form 4, Insider Transaction, Stock Sale, Tax Withholding, 10b5-1 Plan, Restricted Stock